Domain Therapeutics
Pharmaceutical Manufacturing • 
Illkirch-Graffenstaden, Grand Est, France • 51-100 Employees
Company overview
| Headquarters | 220, Boulevard Gonthier d'Andernach, Illkirch-Graffenstaden, Grand Est 67400, FR |
| Phone number | +33390406150 |
| Website | |
| NAICS | 3254 |
| SIC | 873 |
| Keywords | Life Sciences, Biotechnology, Clinical Research, Drug Discovery, Drug Development, Biomarkers, Sustainability, Innovation, Clinical Trials, Precision Medicine, Cancer Research, Immuno-Oncology, Immunotherapy, Cancer, Cancer Treatment, Clinical Development, Inflammation, Sustainable Mobility, Gpcr, Green Mobility, Immune System, Cancer Immunotherapy, Biopharma, Sustainable Transportation, Tumor Biology, Sustainable Future, Tumor Microenvironment, Soft Mobility, Patient-Centered Approach, Immunoresistance, Immunosuppression |
| Founded | 2008 |
| Employees | 51-100 |
| Socials |
Key Contact at Domain Therapeutics
Laurent Sabbagh
Scientific Director R&D
Domain Therapeutics Email Formats
Domain Therapeutics uses 5 email formats. The most common is {first initial}{last name} (e.g., jdoe@domaintherapeutics.com), used 62.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@domaintherapeutics.com | 62.5% |
{first name}{last name} | johndoe@domaintherapeutics.com | 28.6% |
{last name}{last name} | doedoe@domaintherapeutics.com | 3.6% |
{first initial}.{last name} | j.doe@domaintherapeutics.com | 1.8% |
{first name}.{last name} | john.doe@domaintherapeutics.com | 1.8% |
About Domain Therapeutics
Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and deliver innovative immunotherapies to patients. Domain’s proprietary programs include DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, and DT-9081, an EP4 receptor antagonist alongside the M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA. The company has also an optimized pipeline of best-in-class and first-in-class GPCR targets selected through Domain’s proprietary cross-validation drug discovery and development platform.
Domain Therapeutics revenue & valuation
| Annual revenue | $18,000,000 |
| Revenue per employee | $247,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $57,600,000 |
| Total funding | $51,900,000 |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Funding Data
Explore Domain Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Domain Therapeutics Tech Stack
Discover the technologies and tools that power Domain Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Font scripts
Tag managers
Programming languages
Miscellaneous
Video players
Hosting
JavaScript libraries
Blogs
Cookie compliance
Analytics
Databases
Miscellaneous
Denmark
Saudi Arabia
United Kingdom
Australia
United States
Frequently asked questions
4.8
40,000 users
